UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.
Prediction market platform Kalshi has closed a $1 billion Series G funding round at a $40 billion valuation, led by Sequoia Capital and Wellington Management. The valuation represents an 82% increase from its $22 billion valuation in May 2026, as the company expands beyond prediction markets into financial products including crypto and stock perpetual futures.
Predicate, a company that helps digital asset issuers enforce compliance rules, has raised $8 million in Series A funding led by Blockchain Capital. The funding will support the company's mission to help financial firms maintain compliance controls when moving assets onto public blockchains.
Venture capital firm Disruptive raised a $10 billion fund focused on AI and defense technology investments, marking one of the largest venture funds ever raised. The Dallas-based firm plans to make approximately 10 investments from the fund.
Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.
Mach9, originally founded in 2021 as a robotics company for civil engineering visual inspections, has raised $34 million in Series A funding after pivoting to AI-powered CAD software for civil engineering and surveying. The San Francisco startup shifted away from its hardware-focused approach to focus on software solutions.
Coherence Neuro has raised $45 million in funding from OpenAI's venture capital arm and Founders Fund to develop a brain implant designed to detect and treat cancer. The coin-sized device monitors tumor activity through neural signals.
French business planning platform Pigment has raised $250 million in Series E funding at a $2.3 billion valuation. The company, which competes with Microsoft Excel and PowerPoint, is developing an agentic AI platform for performance management.
Arda, a startup founded by former OpenAI research chief Bob McGrew, has raised $230 million at a $1.5 billion valuation to use artificial intelligence to automate and revive U.S. manufacturing. The round was led by Altimeter Capital, Accel, and Khosla Ventures.
Estuary Biotherapeutics, a California-based biotech developing gene therapies for kidney disease, officially launched with $103 million in funding and a management team of former Biogen leaders backed by investors including Biogen.
Current and prospective investors in Anthropic's upcoming IPO are weighing a lower valuation for the AI company after its latest financial disclosures showed revenue growth concerns, with some sources citing the company's crackdown on AI copycats potentially hurting growth.
Salience Labs, an Oxfordshire-based startup, has raised an oversubscribed $125 million Series B funding round led by Bullhound Capital, with participation from AMD Ventures, Intel Capital, and the British Business Bank. The company will use the funds to scale production of its fully optical circuit-switching technology for AI infrastructure and expand operations in California.
AI scribe company Suki has raised $90 million in Series E financing to expand beyond clinical documentation and build AI agents that handle administrative tasks like referrals and prior authorizations. The company plans to deepen partnerships with over 30 technology partners that have embedded its solutions.
Prediction market platform Kalshi is in advanced discussions to raise approximately $1 billion in funding that would value the company at roughly $40 billion, nearly double its May 2026 valuation of $22 billion. Tiger Global and Dragoneer are reportedly in talks to lead the financing.
Venture capital investment in crypto and blockchain companies reached $5.68 billion across 384 deals in the second quarter of 2026, representing a 31% increase from Q1 and a 10% rise in deal count, according to Galaxy Research.
Chinese internet company ByteDance has completed a $290 million fundraising round for its artificial intelligence drug discovery unit after spinning it off as a separate entity called Anew Labs. The funding values the newly independent company at $1.5 billion.
Factory, a San Francisco startup building autonomous AI agents for software engineering, closed a $200 million funding round that values the company at $5 billion. The valuation represents more than triple the $1.5 billion valuation from its previous round five months earlier.
AI company Anthropic has informed its backers it will be profitable this quarter, marking its second consecutive profitable quarter as it prepares for a blockbuster IPO and moves to address investor concerns about cash burn at frontier AI companies.
Nasdaq's venture arm is investing $100 million in Payward, the parent company of cryptocurrency exchange Kraken, valuing the firm at $21 billion. Kraken will distribute tokenized Nasdaq-listed stocks that carry the same voting rights as traditional shares.
Antioch Inc., a year-old startup, secured $32 million in Series A funding led by Greylock to expand its cloud-based simulation platform that enables robot testing without real-world data collection. The funding will support product development and engineering hires as the company offers an alternative to billion-dollar real-world data approaches.
Healthcare automation startup Forus raised $150 million in a Series C round led by Bain Capital Ventures, tripling its valuation to $3 billion in approximately four months. The company uses AI to accelerate patient access to specialty medicines.
NavigateAI, founded by former Opendoor CEO Eric Wu, emerged from stealth in May with $25 million in funding from Elad Gil and Khosla Ventures. The company is developing AI copilots that provide real-time, hands-free guidance to construction workers through smartphones and Meta's AI glasses.
Israeli-Dutch AI startup Wonderful has closed a $550 million Series C funding round led by Insight Partners with participation from Salesforce, valuing the enterprise AI automation company at $5 billion. The valuation represents a 2.5x increase from its $2 billion valuation just six months ago.
AI data company AfterQuery reached a $3.2 billion valuation just 18 months after founding, up from $300 million five months ago, making it Y Combinator's fastest company to reach unicorn status in nearly two decades.
Miami-based fintech Felix Pago closed a $200 million Series B round, with $87 million in equity led by Andreessen Horowitz and $113 million in debt. The company enables WhatsApp-based remittances to Latin America, settling most transfers in USDC without users directly handling crypto.
1789 Capital, where Donald Trump Jr. serves as a partner, is leading a $1 billion funding round for prediction market Polymarket at a $21 billion valuation, with the firm contributing approximately $300 million.
San Francisco-based startup Clipto has raised $15 million in equity financing at a $250 million valuation to expand its AI technology that searches through terabytes of video and forgotten files using natural language queries.
Instinct, a year-old AI assistant startup founded by a 23-year-old, has raised $250 million in Series B funding at a $2.5 billion valuation. The consumer-focused assistant has gained popularity among Silicon Valley tech workers but faces questions about personal data access.
Ringg, an Indian startup developing voice AI agents for business communications, has secured $10 million in funding from Peak XV Partners. The company automates routine business conversations across industries, from clinic bookings to abandoned cart follow-ups, capitalizing on India's strong consumer preference for phone-based communication.
Legato, a hearing technology startup, has emerged from stealth mode with $12 million in funding from Neotribe Ventures, Listen, and Village Global to develop AI-powered hearing glasses. The company aims to address the gap in hearing loss treatment, as only 20% of the estimated 50 million U.S. adults with diagnosed hearing loss currently seek treatment.
Alice, an AI trust and security company formerly known as ActiveFence, raised $140 million in a funding round led by Apax Digital. The Israeli company, which is trusted by Anthropic, Google, and Cohere, has grown its AI security business more than 500% and is approaching $100 million in annual recurring revenue.
Crypto and blockchain companies announced approximately $1.298 billion in funding across six disclosed transactions between Aug. 16 and Aug. 22, 2026, with ZeroStack accounting for $1 billion and Ripple raising $275 million.
Rillet, a two-year-old startup building an AI-native accounting platform, raised $100 million in Series C funding at a $1 billion valuation. The funding round was completed in just 48 hours following a routine board meeting that triggered an extraordinary investor rush.
Anthropic is assembling a revolving credit facility exceeding $10 billion ahead of a potential IPO, with lead banks asked to lend about $1.25 billion each. The company is also exploring a $6-7 billion acquisition of Israeli AI startup Decart.
Anthropic's revolving credit facility is expected to rise above its roughly $10 billion target as the AI company prepares for a highly anticipated IPO. The company is also preparing to give CEO Dario Amodei and co-founders shares with extra voting power ahead of the public listing.
AI hardware startup Etched raised $700 million at a $21 billion valuation in a round led by Jane Street, after the quantitative trading firm tested and purchased the company's systems. The valuation doubled from $10.3 billion just weeks earlier.
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.